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Abstract
Human papillomaviruses (HPV) are a major cause of malignancy worldwide, contributing to ~5% of all human cancers
including almost all cases of cervical cancer and a growing number of ano-genital and oral cancers. HPV-induced
malignancy is primarily driven by the viral oncogenes, E6 and E7, which manipulate host cellular pathways to increase cell
proliferation and enhance cell survival, ultimately predisposing infected cells to malignant transformation. Consequently, a
more detailed understanding of viral-host interactions in HPV-associated disease offers the potential to identify novel
therapeutic targets. Here, we identify that the c-Jun N-terminal kinase (JNK) signalling pathway is activated in cervical
disease and in cervical cancer. The HPV E6 oncogene induces JNK1/2 phosphorylation in a manner that requires the E6
PDZ binding motif. We show that blockade of JNK1/2 signalling using small molecule inhibitors, or knockdown of the
canonical JNK substrate c-Jun, reduces cell proliferation and induces apoptosis in cervical cancer cells. We further
demonstrate that this phenotype is at least partially driven by JNK-dependent activation of EGFR signalling via increased
expression of EGFR and the EGFR ligands EGF and HB-EGF. JNK/c-Jun signalling promoted the invasive potential of
cervical cancer cells and was required for the expression of the epithelial to mesenchymal transition (EMT)-associated
transcription factor Slug and the mesenchymal marker Vimentin. Furthermore, JNK/c-Jun signalling is required for the
constitutive expression of HPV E6 and E7, which are essential for cervical cancer cell growth and survival. Together, these
data demonstrate a positive feedback loop between the EGFR signalling pathway and HPV E6/E7 expression, identifying a
regulatory mechanism in which HPV drives EGFR signalling to promote proliferation, survival and EMT. Thus, our study
has identified a novel therapeutic target that may be beneficial for the treatment of cervical cancer.
Introduction
Persistent infection with human papillomavirus (HPV) is
the underlying cause of most cervical cancers and several
other anogenital and oropharngeal cancers [1]. These can-
cers are predominantly caused by HPV16 and HPV18;
however, 13 other high-risk HPV types are also associated
with cancer development [2]. HPV-induced transformation
is primarily driven by three virus-expressed oncogenes: E5,
E6 and E7. HPV E5 functions as an ion channel, induces
EGFR signalling and promotes resistance to anti-PD-L1
immunotherapy [3–6]. E6 and E7 are the primary drivers of
viral oncogenesis; in addition to their well-characterised
inactivation of the p53 and pRb tumour suppressors [7, 8],
they regulate a multitude of signalling pathways that con-
tribute to transformation [9–15].
Mitogen-activated protein kinases (MAPK) convert
extracellular stimuli into a range of cellular responses [16].
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The MAPKs extracellular signal-regulated kinase (ERK)
and p38 have been shown to have important roles in the
HPV life cycle and in HPV-induced transformation [17–
19]. In contrast, less is known about the role of the c-Jun N-
terminal kinases (JNK).
JNKs consist of 10 isoforms, generated via alternative
splicing from three genes: JNK1 and JNK2 (four isoforms
of each) are ubiquitously expressed, whereas JNK3 (two
isoforms) is mainly expressed in the brain, heart and testes
[20]. JNK signalling can regulate tumour suppressive and
oncogenic functions [21]. In combination with oncogenic
Ras, JNK can either suppress or promote oncogenesis [22–
24]. JNK can also promote malignancy in combination with
PTEN loss or expression of the BCR-Abl oncogene
[25, 26]. Interestingly, JNK1 and JNK2 can have opposing
roles during tumour development, making JNK signalling
not only complex but also tissue-type specific [27, 28].
We previously observed increased JNK1/2 phosphor-
ylation in primary normal human keratinocytes (NHK)
stably harbouring the HPV18 genome [29]; however, it is
not known if JNK contributes to transformation in HPV-
associated cancers. In this study, we demonstrate that
phosphorylation of JNK1/2 and its substrate c-Jun is
enhanced in HPV+ cervical cancer. We show that JNK1/
2 signalling is critical for the proliferative and invasive
properties of cervical cancer cells and is required for basal
and growth factor-induced viral oncogene expression.
Together, we identify a host signalling pathway that plays a
key role in cervical cancer progression that could potentially
serve as a therapeutic target for HPV-associated cancers.
Results
c-Jun N-terminal kinase 1/2 (JNK1/2)
phosphorylation is increased in cervical cancer
We have published that JNK1/2 phosphorylation is
increased in NHKs containing the HPV18 genome when
compared to donor-matched control primary cells ([29];
Fig. 1A). We therefore investigated the role of JNK sig-
nalling in HPV-associated disease. JNK1/2 phosphorylation
was analysed in cytology samples from a cohort of HPV16+
patients with cervical intraepithelial neoplasia (CIN); CIN1
represents a transient HPV infection with mild dysplasia,
while CIN3 represents severe dysplasia [30]. Cytology
samples from healthy, HPV-negative (HPV−) patients were
used as controls. JNK1/2 phosphorylation increased during
progression through CIN1 to CIN3, whilst total JNK1/2
expression remained constant (Fig. 1B; quantified in
Fig. 1C). We next examined JNK1/2 phosphorylation in a
panel of cervical cancer cell lines. Compared to NHKs,
JNK1/2 phosphorylation was higher in all cervical cancer
cells and was highest of all in HPV-positive (HPV+) cells
(Fig. 1D). To determine if this extended to cervical cancer
tissue, we performed immunohistochemistry (IHC) on a
cervical cancer tissue microarray (TMA). JNK1/2 phos-
phorylation was significantly higher in the cervical cancer
tissue when compared to control tissue (Fig. 1E). These data
demonstrate that JNK1/2 phosphorylation is increased dur-
ing cervical disease progression and in cervical cancer.
JNK1/2 are required for c-Jun/AP-1 activity in
cervical cancer
JNKs accomplish many of their functions by phosphor-
ylating and activating Activator Protein-1 (AP-1) tran-
scription factors [31]. We focused on Jun proteins, as these
are commonly associated with tumourigenesis, particularly
in cancers arising from keratinocytes, and c-Jun is a major
cellular substrate of JNK [32, 33]. We observed increased c-
Jun and JunD transcript and protein levels in HPV18 con-
taining keratinocytes (Supplementary Fig. 1A, B). This
increase was also seen in HPV+ cancer cells (Supplemen-
tary Fig 1C, D). In contrast, JUNB expression was
unchanged (Supplementary Fig. 1A and C). Finally, using
data from The Cancer Genome Atlas (TCGA), we observed
that JUN expression significantly correlated with reduced
survival in cervical cancer patients, whereas JUND
expression did not (Supplementary Fig. 1E). We therefore
focused on c-Jun as a potential downstream target of JNK1/
2 in subsequent studies.
The transcriptional activity of c-Jun is regulated by
Ser63/Ser73 phosphorylation [34]. ERK, JNK and p38 are
all reported to phosphorylate these sites [34–36]. Using a
reverse-phase protein array (RPPA) data set [37, 38],
phosphorylation of ERK1/2 and JNK1/2, but not p38, sig-
nificantly correlated with c-Jun phosphorylation in cervical
cancer (Fig. 2A). To validate this, we used specific inhibi-
tors targetting MEK1/2 (which inhibits ERK1/2), JNK1/2
and p38 and assessed c-Jun phosphorylation. Inhibition of
p38 had no effect on c-Jun phosphorylation, whilst ERK1/2
inhibition led to a small (~30%) decrease in c-Jun phos-
phorylation. Crucially, inhibition of JNK1/2 using two
chemically distinct inhibitors resulted in a ~70% and ~90%
reduction, suggesting that JNK1/2 are the primary kinases
required for c-Jun phosphorylation in HPV+ cervical can-
cer cells (Fig. 2B). Pharmacological inhibition of JNK1/2
also resulted in a ~75% reduction in AP-1 transcriptional
activity (Fig. 2C). To investigate if c-Jun was required for
AP-1 signalling in these cells, we depleted c-Jun expression
which resulted in a ~50% reduction in AP-1 activity
(Fig. 2D). Over-expression of c-Jun resulted in a ~2.5-fold
increase in AP-1 activity (Fig. 2E), together suggesting that
JNK/c-Jun signalling drives AP-1 activity in HPV+ cervi-
cal cancer cells.
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HPV E6 induces JNK1/2 phosphorylation via the
PDZ-binding motif (PBM)
Expression of HPV18 E6 in C33A cells and NHKs
increased JNK1/2 phosphorylation (Fig. 3A), whilst E7
expression only slightly increased JNK1/2 phosphorylation
and did not significantly enhance JNK1/2 phosphorylation
when co-expressed with E6. Further, depletion of endo-
genous E6/E7 by siRNA reduced the level of JNK1/2
phosphorylation in both HeLa and CaSKi cells (Fig. 3B).
Fig. 1 c-Jun N-terminal kinases are significantly phosphorylated in
HPV+ cervical cancer. A Representative western blot of normal
human keratinocytes (NHK) and NHKs containing the HPV18 gen-
ome (HPV18) analysed for phosphorylated JNK1/2 and total JNK
expression. GAPDH served as a loading control. Data shown are
representative of at least three independent experiments. B Repre-
sentative western blot from cytology samples of CIN lesions of
increasing grade analysed for phosphorylated JNK1/2 and total JNK
expression. GAPDH served as a loading control. C Scatter plot of
densitometry analysis of a panel of cytology samples. Twenty samples
from each clinical grade (Neg, CIN 1–3) were analysed by western
blot and densitometry analysis was performed for phosphorylated
JNK1/2 and total JNK expression. D Representative western blot
analysis of a panel of six cervical cancer cell lines—two HPV− (C33A
and DoTc2 4510), two HPV16+ (SiHa and CaSKi) and HPV18+
(SW756 and HeLa)—and NHK cells for phosphorylated JNK1/2 and
total JNK. GAPDH served as a loading control. Densitometry analysis
of phosphorylated JNK1/2, normalised to total JNK and GAPDH
expression, from three independent experiments is shown below.
E Representative results of immunohistochemical staining for phos-
phorylated JNK1/2 expression in cervical cancer tissues and adjacent
non-tumour tissues. Images were acquired using identical exposure
times. Scale bar, 50 μm. Statistical analysis for phosphorylated JNK1/2
expression in cervical cancer tissues (n= 39) compared with non-
tumour tissues (n= 9) is shown on the right. Each section was stained
and analysed in duplicate. Phosphorylated JNK1/2 was quantified in
an automated fashion using the IHC Profiler Plug-in for ImageJ. Error
bars represent the mean+/− standard deviation. *P < 0.05, **P <
0.01, ***P < 0.001 (Student’s t-test).
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Given that HPV E6 induced JNK1/2 phosphorylation, we
investigated if E6 was responsible for the observed JNK-
dependent AP-1 activity. Expression of HPV18 E6
increased c-Jun phosphorylation and enhanced AP-1 activ-
ity (Fig. 3C, D). Importantly, the increase in c-Jun phos-
phorylation and AP-1 activity was abolished in cells treated
with inhibitors of JNK1/2.
To gain a greater insight into how HPV E6 increased
JNK1/2 phosphorylation, we utilised a number of well-
characterised E6 mutants. Both HPV18 E6-F4V, which
cannot induce p53 degradation [39], and E6-L52A,
which inhibits the interaction with E6AP [40], increased
JNK1/2 phosphorylation to levels comparable with wild
type (WT) E6. In contrast, an E6 mutant lacking the
carboxyl-terminal PBM (ΔPDZ; [41]) failed to increase
JNK1/2 phosphorylation, suggesting that E6 binding to
PDZ-domain-containing proteins is required for JNK1/2
phosphorylation (Fig. 3E). This observation was also
confirmed with the HPV16 E6 protein (Fig. 3E). Only E6
proteins from high-risk HPV types contain a PBM. In
agreement with this, expression of E6 from the α-genus
low-risk types 11, or the β-genus types HPV8 and
HPV38 did not increase JNK1/2 phosphorylation
(Fig. 3F). Together, these data demonstrate that high-risk
E6 induces JNK1/2 phosphorylation in a PBM-dependent
manner.
Fig. 2 JNK activity is required for c-Jun/AP-1 activity in cervical
cancer. A Scatter plot of expression levels of c-Jun phosphorylation
and JNK phosphorylation, ERK phosphorylation and p38 phosphor-
ylation as analysed using the MD Anderson public RPPA data set. The
correlation coefficient (r) was calculated using Spearman’s rank ana-
lysis. B Representative western blot of HeLa cells treated with the p38
inhibitor SB203580 (10 µM), the MEK1/2 inhibitor U0126 (10 µM), or
the JNK inhibitors SP600125 (10 µM) and JNK-IN-8 (3 µM). Lysates
were analysed for phosphorylated and total c-Jun, phosphorylated and
total ERK and phosphorylated and total MAPKAP2. GAPDH served
as a loading control. Data shown are representative of at least three
independent experiments. C Representative luciferase reporter assay
from HeLa cells transfected with an AP-1 luciferase reporter, in the
presence or absence of JNK-IN-8 (3 µM) or SP600125 (10 µM). Pro-
moter activity was measured using a dual-luciferase system. Data are
presented as relative to the DMSO control. D Luciferase reporter assay
from HeLa cells co-transfected with an AP-1 luciferase reporter and
pool of siRNA against the JNK substrate c-Jun. Promoter activity was
measured using a dual-luciferase system. Data are presented as relative
to the scrambled siRNA transfection control. E Representative luci-
ferase reporter assay from HeLa cells co-transfected with an AP-1
luciferase reporter and c-Jun. Promoter activity was measured using a
dual-luciferase system. Data are presented as relative to the pcDNA
transfection control. Error bars represent the mean+/− standard
deviation of a minimum of three biological repeats. *P < 0.05, **P <
0.01, ***P < 0.001 (Student’s t-test).
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Fig. 3 HPV E6 induces JNK phosphorylation via its PDZ-binding
domain. A Representative western blot of C33A and NHK cells
transiently transfected with GFP or GFP tagged HPV18 E6, E7 and E6/
E7 and analysed for phosphorylated JNK1/2 and total JNK expression.
Expression of HPV oncoproteins was confirmed by fluorescence
microscopy for GFP expression (not shown) and HPV18 E6 and
HPV18 E7 specific antibodies. GAPDH served as a loading control.
Data shown are representative of at least three independent experi-
ments. B Representative western blot of HeLa and CaSKi cells trans-
fected with a pool of specific siRNAs against HPV18 E6/E7 or HPV16
E6/E7 respecitvely and analysed for phosphorylated JNK1/2 and total
JNK expression. GAPDH served as a loading control. Data shown are
representative of at least three independent experiments. C Repre-
sentative western blot of C33A cells co-transfected with GFP or GFP
tagged E6, in the presence or absence of JNK-IN-8 (3 µM). Lysates
were analysed for phosphorylated c-Jun and total c-Jun expression.
GAPDH served as a loading control. Data shown are representative of
at least three independent experiments. D Luciferase reporter assay
from C33A cells co-transfected with GFP or GFP tagged E6, and an
AP-1 luciferase reporter, in the presence or absence of JNK-IN-8 (3
µM) or SP600125 (10 µM). Promoter activity was measured using a
dual-luciferase system. Data are presented as relative to the GFP
transfection control. E Representative western blot of C33A cells
transiently transfected with GFP tagged E6 and E6 mutants and ana-
lysed for phosphorylated JNK and total JNK expression. Expression of
HPV E6 and mutants was confirmed using a GFP antibody and
GAPDH served as a loading control. Data shown are representative of
at least three independent experiments. F Representative western blot
of C33A cells co-transfected with GFP tagged E6 from different HPV
types and analysed for phosphorylated JNK and total JNK expression.
Expression of HPV E6 proteins was confirmed using a GFP antibody
and GAPDH served as a loading control. Data shown are representative
of at least three independent experiments. Error bars represent the
mean+/− standard deviation of a minimum of three biological repeats.
*P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test).
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Inhibition of JNK activity is detrimental to HPV+
cervical cancer cell proliferation
JNK signalling can promote or inhibit cell proliferation,
depending on the cellular context [22, 23]. To assess the
impact of JNK/c-Jun activity on cell proliferation, we
treated HeLa and CaSKi cells with increasing doses of the
JNK1/2 inhibitors JNK-IN-8 and SP600125 [42, 43].
Inhibition of JNK1/2 resulted in a dose-dependent loss of
c-Jun phosphorylation (Fig. 4A and Supplementary
Fig. 2A). There was also a reduction in c-Jun expression, as
c-Jun positively regulates its own transcription [44]. Inhi-
bition of JNK1/2 led to a significant decrease in cell growth
(Fig. 4B) and anchorage-dependent and anchorage-
independent colony formation (Fig. 4C, D). Conversely,
inhibition of JNK1/2 in HPV- C33A cells had minimal
impact on cell growth or colony formation, despite a dose-
dependent loss of c-Jun phosphorylation and protein
expression (Supplementary Fig. 4A–D), suggesting that
HPV+ cervical cancer cells are more sensitive to the
effects of JNK1/2 inhibition, corresponding with higher
levels of JNK1/2 phosphorylation.
Previous studies have demonstrated distinct effects of
JNK1 and JNK2 in tumourigenesis [45, 46]. To investigate
the contribution of each JNK gene, we utilised dominant-
negative JNK1 and JNK2 mutants, in which the phos-
phorylation motif TPY is mutated to APF, resulting in JNK
proteins that cannot be activated or phosphorylate c-Jun
(Supplementary Fig. 3A; [47]). We found that both JNK1
and JNK2 are required for cell growth (Supplementary
Fig. 3B) and colony formation (Supplementary Fig. 3C–D).
These data demonstrate that the activity of both JNK1 and
JNK2 is required for the proliferative ability of HPV+
cervical cancer cells.
Active c-Jun/AP-1 is required for the proliferation of
HPV+ cervical cancer cells
To confirm whether the JNK-dependent cell proliferation
we observed was mediated by c-Jun/AP-1 signalling, we
either depleted or over-expressed c-Jun (Fig. 4E and Sup-
plementary Fig. 5A). Depletion of c-Jun significantly
reduced cell growth (Fig. 4F) and colony formation
(Fig. 4G, H). Conversely, over-expression of c-Jun
enhanced cell growth and colony formation (Supplemen-
tary Fig. 5B-D), suggesting that c-Jun is required for the
proliferation of HPV+ cervical cancer cells. In addition, we
transfected cells with a dominant-negative JunD (ΔJunD)
lacking a transcriptional activation domain that can dimer-
ize with other AP-1 proteins and inhibit AP-1 activation
(Supplementary Fig. 6A; [48]). ΔJunD expression abol-
ished AP-1 activity in HeLa cells (Supplementary Fig. 6,
B), and inhibited cell growth and colony formation
(Supplementary Fig. 6C–E). These data suggest that JNK/c-
Jun/AP-1 signalling is required for the proliferation of
HPV+ cervical cancer cells.
Inhibition of JNK/c-Jun induces G2/M phase
accumulation and apoptosis in cervical cancer cells
We investigated if the reduced HPV+ cell proliferation
caused by JNK inhibition was caused by modulation of the
cell cycle. JNK1/2 inhibition led to a significant increase of
cells in the G2/M phase, suggesting that JNK activity was
required for progression from G2 into mitosis, or release
from mitosis into G1 (Supplementary Fig. 7A). Depletion of
c-Jun led to a similar effect on cell cycle progression
(Supplementary Fig. 7D).
Interestingly, inhibition of JNK1/2 or depletion of c-Jun
also resulted in a significant increase in the proportion of
cells in sub-G1, which is indicative of apoptosis (Supple-
mentary Fig. 7A and D). We performed Annexin V assays
and demonstrated that inhibition of JNK/c-Jun by either
approach led to an increase in early and late apoptosis,
demonstrating that JNK signalling is required for cell sur-
vival in HPV+ cervical cancer cells (Supplementary Fig. 7,
B and E). Mechanistically, we demonstrated that loss of
JNK activity or c-Jun expression correlated with the acti-
vation of caspase 3, increasing the proteolytic cleavage of
PARP (Supplementary Fig. 7C and F). Together, these data
suggest that JNK/c-Jun signalling is required for cell cycle
progression and survival in HPV+ cervical cancer cells.
JNK/c-Jun activity is required for cell migration/
invasion and regulates epithelial to mesenchymal
transition (EMT) in cervical cancer cells
Despite current survival rates demonstrating that existing
treatments can be successful in cervical cancer (50–60%
with radiotherapy and concurrent cisplatin treatment), many
cases develop local recurrences and metastasise [49]. Fur-
thermore, epithelial-mesenchymal transition (EMT) has
been shown to increase cervical cancer progression via
increased cell migration and invasion [50]. JNK signalling
is a key driver of cell invasion in many cancers [51, 52]. We
therefore investigated if JNK/c-Jun signalling contributed to
the invasive phenotype of cervical cancer cells. Inhibition of
JNK1/2 or depletion of c-Jun significantly reduced both the
migration and invasion of cervical cancer cells through a
Transwell® chamber membrane (Fig. 5A–D).
EMT and associated extracellular matrix remodelling are
key processes enabling cancer cell invasion. JNK1/2 inhibi-
tion or c-Jun depletion reduced expression of matrix metal-
loprotease (MMP)-9, a crucial enzyme involved in cancer cell
invasion (Fig. 5E, F). In addition, the expression of the EMT-
associated transcription factors Slug (SNAI2) and ZEB1
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Fig. 4 Inhibition of JNK/c-Jun signalling impaires the prolifera-
tion of HPV+ cervical cancer cells. A Representative western blots
of HeLa and CaSKi cells treated with increasing doses of JNK-IN-8.
Lysates were analysed for the phosphorylation and expression of the
JNK substrate c-Jun. GAPDH was used as a loading control. Data
shown are representative of at least three independent experiments.
B Growth curve analysis of HeLa and CaSKi cells treated with JNK-
IN-8 (3 µM) or SP600125 (10 µM). C Colony formation assay
(anchorage-dependent growth) of HeLa and CaSKi cells treated with
JNK-IN-8 (3 µM) or SP600125 (10 µM). D Soft agar assay (ancho-
rage-independent growth) of HeLa and CaSKi cells treated with JNK-
IN-8 (3 µM) or SP600125 (10 µM). E Representative western blots of
HeLa and CaSKi transfected with a pool of siRNA against c-Jun.
Lysates were analysed for the expression of c-Jun. GAPDH was used
as a loading control. Data shown are representative of at least three
independent experiments. F Growth curve analysis of HeLa and
CaSKi cells transfected with a pool of siRNA against c-Jun. G Colony
formation assay (anchorage-dependent growth) of HeLa and CaSKi
cells transfected with a pool of siRNA against the JNK substrate c-Jun.
H Soft agar assay (anchorage-independent growth) of HeLa and
CaSKi cells transfected with a pool of siRNA against c-Jun. Error bars
represent the mean+/− standard deviation of a minimum of three
biological repeats. *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-
test).
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Fig. 5 JNK/c-Jun activity is required for cell migration/invasion and
regulates epithelial to mesenchymal transition (EMT). A Transwell®
migration assay of HeLa and CaSKi cells treated with JNK-IN-8 (3 µM) or
SP600125 (10 µM). The average number of invaded cells per field was
calculated from five representative fields per experiment. B Transwell®
invasion assay of HeLa and CaSKi cells treated with JNK-IN-8 (3 µM) or
SP600125 (10 µM). The average number of invaded cells per field was
calculated from five representative fields per experiment. C Transwell®
migration assay of HeLa and CaSKi cells after transfection of a pool of
siRNA against c-Jun. The average number of invaded cells per field was
calculated from five representative fields per experiment. D Transwell®
invasion assay of HeLa and CaSKi cells after transfection of a pool of
siRNA against c-Jun. The average number of invaded cells per field was
calculated from five representative fields per experiment. E qPCR analysis
of MMP9 mRNA expression HeLa and CaSKi cells treated with JNK-IN-
8 (3 µM) or SP600125 (10 µM). U6 was used as a loading control. F
qPCR analysis of MMP9 mRNA expression HeLa and CaSKi cells cells
after transfection of a pool of siRNA against c-Jun. U6 was used as a
loading control.G qPCR analysis of genes involved in EMT in HeLa cells
treated with JNK-IN-8 (3 µM) or SP600125 (10 µM). U6 was used as a
loading control. H qPCR analysis of genes involved in EMT in CaSKi
cells treated with JNK-IN-8 (3 µM) or SP600125 (10 µM). U6 was used as
a loading control. I qPCR analysis of genes involved in EMT in HeLa and
CaSKi cells after transfection of a pool of siRNA against c-Jun. U6 was
used as a loading control. J Representative western blots of HeLa and
CaSKi treated JNK-IN-8 (3 µM) or SP600125 (10 µM). Lysates were
probed for the expression of Slug, Snail, Vimentin, ZO-1 and ZEB1.
GAPDH was used as a loading control. Data shown are representative of
at least three independent experiments. K Representative western blots of
HeLa and CaSKi after transfection of a pool of siRNA against c-Jun.
Lysates were probed for the expression of Slug, Snail, Vimentin, ZO-1 and
ZEB1. GAPDH was used as a loading control. Data shown are repre-
sentative of at least three independent experiments. Error bars represent the
mean+/− standard deviation of a minimum of three biological repeats.
*P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t-test).
E. L. Morgan et al.
(ZEB1), but not Snail (SNAI1), and the mesenchymal markers
N-cadherin (CDH2) and vimentin (VIM), was also reduced
(Fig. 5G–K). Conversely, expression of the epithelial markers
E-cadherin (CDH1) and ZO-1 (TJP1) was increased, sug-
gesting that JNK/c-Jun activity is required for the invasive
potential of cervical cancer cells, potentially through the
regulation of EMT-associated proteins.
JNK activity promotes EGFR signalling to regulate
proliferation
In keratinocytes, proliferation is often mediated via binding
of the epidermal growth factor (EGF)-family of ligands to
the EGF receptor (EGFR) [32, 53, 54]. Several EGF-family
ligands, as well as the EGFR itself, are regulated by c-Jun
[55–57]. As EGFR signalling can be regulated by HPV E6
[58], we investigated whether the EGFR was required for
the enhanced JNK activity observed. For this, HeLa cells
were serum starved and treated with EGF (Supplementary
Fig. 8). EGF treatment caused rapid and transient EGFR
autophosphorylation (Y1068) and rapidly induced JNK1/2
phosphorylation, which peaked 10 min post-treatment and
was undetectable 30 min post-treatment. This was followed
by phosphorylation of the JNK substrates c-Jun and JunD,
which started 15 min post treatment and peaked 45 min post
treatment. By 1 h, an increase in both c-Jun and JunD
protein expression was observed. These data show that EGF
activated the JNK/c-Jun signalling pathway in cervical
cancer cells.
We next investigated if the JNK/c-Jun pathway regulated
EGFR signalling in cervical cancer cells. First, we inhibited
JNK activity and used qRT-PCR to measure the expression
of EGFR and the EGFR ligands EGF, transforming growth
factor α (TGFα) and heparin-binding EGF (HB-EGF).
Inhibition of JNK activity significantly reduced EGFR,
EGF and HBEGF expression, without affecting the
expression of TGFA (Fig. 6A). This led to a loss of EGFR
protein expression (Fig. 6B). Knockdown of c-Jun had
similar effects (Fig. 6C, D), suggesting that JNK/c-Jun
signalling regulated the expression of key EGFR signalling
components in cervical cancer cells. Data from the TCGA
demonstrated that c-Jun expression correlated with EGFR,
EGF and HBEGF expression (Fig. 6E).
Next, we assessed if impaired EGFR signalling was
responsible for the reduction in proliferation observed upon
inhibition of the JNK/c-Jun pathway. To do this, we incu-
bated cells previously treated with DMSO or SP600125 (as
SP600125 is a reversible inhibitior [42]) in conditioned
media from cells treated with DMSO or SP600125 (diagram
in Fig. 6F). Incubation of DMSO treated cells with condi-
tioned media taken from SP600125-treated cells sig-
nificantly reduced colony formation (Fig. 6G, compare bar
2 to bar 1). To determine if this was due to impaired EGF/
HB-EGF-EGFR signalling, we supplemented conditioned
media from SP600125 cells with EGF or HB-EGF. The
addition of either EGFR ligand restored colony formation to
control levels (Fig. 6G, compare bars 3 and 4 with bar 1).
We confirmed that the restoration of colony formation was
due to EGFR signalling, as co-incubation of EGF or HB-
EGF with a neutralising EGFR antibody nullified this effect
(compare bars 3 and 4 with bars 5 and 6).
To confirm these findings, we incubated SP600125-
treated cells, which exhibit reduced colony formation
(Fig. 4C), with conditioned media from DMSO treated
cells, which should contain normal levels of EGF and HB-
EGF. In agreement with our previous data, this restored
colony formation to control levels (Fig. 6G, compare bar 7
with bar 1). This supports the hypothesis that a soluble
factor may rescue proliferation in cells in which JNK1/2
was inhibited. The addition of media containing a neu-
tralising EGFR antibody failed to rescue colony formation,
suggesting that EGFR signalling plays a role in the dimin-
ished proliferative ability of JNK-inhibited cervical cancer
cells (Fig. 6G, compare bar 8 with bar 7). Finally, to con-
firm if EGF and/or HB-EGF were the EGFR ligands
implicated in the restoration of proliferation, we incubated
conditioned media from DMSO treated cells with neu-
tralising antibodies against EGF and/or HB-EGF. The
addition of media containing either or both neutralising
antibodies failed to rescue colony formation (Fig. 6G,
compare bars 9, 10 and 11 with bar 7). Taken together,
these data suggest that EGF/HB-EGF-EGFR signalling is
required for the proliferative ability of HPV+ cervical
cancer cells, and this signalling axis is reduced in cells in
which JNK is inhibited.
JNK mediated c-Jun activation plays a critical role in
HPV oncogene expression
The continued expression of the viral oncogenes E6 and E7
is required for the proliferation and survival of HPV-
associated cancers [59]. Viral oncogene expression is
regulated by host transcription factors through binding to
the upstream regulatory region (URR) in the virus genome
[60]. The URR contains AP-1 binding sites in both the
promoter and enhancer regions that can bind c-Jun and
induce E6/E7 expression [61–65]. The signalling that gov-
erns this AP-1 dependent induction of E6/E7 is unclear. To
investigate if JNK signalling played a role, we assessed the
activity of the viral URR using a reporter construct con-
taining the HPV18 URR sequence [65]. Inhibition of JNK1/
2 led to a ~90% reduction in URR-driven luciferase levels,
suggesting that JNK signalling is critical for viral tran-
scription (Fig. 7A). In addition, treatment of HeLa and
CaSKi cells with JNK inhibitors resulted in a significant
reduction in E6/E7 mRNA expression (Fig. 7B). Depletion
E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein. . .
Fig. 6 Regulation of EGFR signalling contributes to JNK mediated
proliferation. A qPCR analysis of EGFR and EGFR ligand expression in
HeLa and CaSKi cells treated with JNK-IN-8 (3 µM) or SP600125 (10
µM) for 48 h. U6 was used as a loading control. B) Representative
western blots of HeLa and CaSKi cells treated with JNK-IN-8 (3 µM) or
SP600125 (10 µM) for the expression of EGFR for 48 h. Data shown are
representative of at least three independent experiments. C qPCR analysis
of EGFR and EGFR ligand expression in HeLa and CaSKi cells after
transfection of a pool of siRNA against c-Jun for 72 h. U6 was used as a
loading control. D Representative western blot of HeLa and CaSKi cells
after transfection of a pool of siRNA against c-Jun for the expression of
EGFR for 72 h. Data shown are representative of at least three indepen-
dent experiments. E Scatter plot of expression levels of JUN and EGFR,
EGF and HBEGF as analysed using the MD Anderson public RPPA data
set. The correlation coefficient (r) was calculated using Spearman’s rank
analysis. F Schematic for conditioned media rescue assay. G Colony
formation assay (anchorage-dependent growth) of HeLa and CaSKi
treated with SP600125 (10 µM) or DMSO control for 48 h. SP600125
was subsequently washed out and control or SP600125-treated cells were
grown in conditioned media from cells treated with DMSO or SP600125.
In addition, cells were also grown in SP600125 conditioned media con-
taining EGF, HB-EGF, or DMSO conditioned media with or without
neutralising EGFR, EGF or HB-EGF antibodies. Colonies were stained
and counted after 14 days. Error bars represent the mean+/− standard
deviation of a minimum of three biological repeats. *P < 0.05, **P <
0.01, ***P < 0.001 (Student’s t-test).
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of the JNK substrate c-Jun also reduced E6/E7 mRNA
(Fig. 7C) and protein (Fig. 7D, E) expression.
ChIP analysis was used to confirm if JNK1/2 inhibition
resulted in reduced c-Jun recruitment to the viral URR,
utilising primers covering the AP-1 binding sites in both the
viral promoter and enhancer. JNK inhibition led to a
significant reduction in c-Jun recruitment to the AP-1
binding sites in both the viral promoter and enhancer
(Fig. 7F).
As we had demonstrated a role for EGF signalling in
JNK activity, we assessed if JNK was responsible for EGF-
induced E6/E7 expression. Treatment of HeLa cells with
E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein. . .
EGF increased viral transcription and E6/E7 expression
(Fig. 7G–I); critically, inhibition of JNK abolished this
EGF-induced oncoprotein expression. Further, EGF stimu-
lation increased binding of c-Jun to the viral URR in a JNK-
dependent manner (Fig. 7J). As expected, depletion of c-Jun
also led to a reduction in EGF-induced viral transcription
and E6/E7 expression, demonstrating that c-Jun is required
for the EGF-induced E6/E7 expression (Fig. 7K, L).
Discussion
Despite the availability of preventative vaccines against
HPV, there is a lack of specific therapies targetting HPV-
associated malignancies. As such, there is a critical need for
research into the fundamental biology of the virus-host
interactions to identify host factors that are essential in
HPV-associated cancers. Indeed, targetting host cell pro-
teins with small molecule inhibitors or nucleic acid mimics
has shown potential as antiviral therapies for a number of
oncogenic viruses, including Kaposi’s sarcoma-associated
herpesvirus (KSHV; [66]) and HPV [14, 67]. HPV
manipulates signalling pathways which contribute to its
oncogenic potential, including the JAK/STAT [13, 14, 29],
PI3K/AKT [10, 68], Hippo [69] and MAPK pathways
[17, 19]. Here, we show aberrant JNK signalling in HPV-
containing keratinocytes and cervical cancer cells.
JNK activity can be either tumour suppressive or onco-
genic, depending on the cellular context. For instance, JNK
activity is associated with the induction of apoptosis and can
suppress Ras-induced transformation in MEF xenografts
[23]. In contrast, JNK is essential for transformation by
oncogenic Ras in lung carcinoma and c-Met in mouse
fibroblasts [22, 70]. Many of these pro-oncogenic functions
of JNK are dependent on the c-Jun transcription factor
[25, 32]. Thus, the function of JNK activity is cancer and
cell-type specific. Using a combination of samples from
patients with cervical disease and cervical cancer tissue, we
show that JNK1/2 phosphorylation correlates with cervical
disease progression and is increased in cervical cancer tissue
and in HPV+ cervical cancer cell lines. This corresponds
with previous data demonstrating high levels of JNK1/2
phosphorylation in cervical cancer [71]. Our data demon-
strate that the increased JNK1/2 phosphorylation correlates
with enhanced c-Jun phosphorylation and AP-1 activity,
which is a key regulator of proliferation in many malig-
nancies, including cervical cancer [72–74]. Importantly, we
demonstrate that inhibition of JNK1/2 using small molecule
inhibitors, inactive mutants and depletion of the JNK sub-
strate c-Jun reduces cell proliferation and increases
apoptosis.
We also observed that the inhibition of JNK1/2 in
HPV+ cervical cancer cells increased the proportion of
cells in the G2 phase of the cell cycle, consistent with
previous reports [75]. This can lead to endoreduplication,
mitotic spindle deformation and delayed apoptosis [76, 77].
The increase in sub-G1 DNA observed upon JNK1/2
inhibition in this study suggests that the mechanism of
apoptosis observed in cervical cancer cells may be due to
mitotic defects.
In addition, we demonstrate that the reduced proliferative
capacity of HPV+ cells observed upon JNK1/2 inhibition
is at least partially due to a defect in EGFR signalling,
Fig. 7 JNK mediated c-Jun activation plays a significant role in
HPV oncogene expression. A Luciferase reporter assay from HeLa
cells transfected with a HPV18 URR luciferase reporter with or
without treatment with JNK-IN-8 (3 µM). Promoter activity was
measured using a dual-luciferase system. Data are presented as relative
to the DMSO control. B qPCR analysis of HPV 16/18 E6 and E7
mRNA expression in HeLa and CaSKi cells treated with JNK-IN-8 (3
µM). U6 was used as a loading control. C qPCR analysis of HPV 16/
18 E6 and E7 mRNA expression in HeLa and CaSKi cells after
transfection of a pool of siRNA against c-Jun. U6 was used as a
loading control. D Representative western blots of HeLa and CaSKi
treated with increasing doses of JNK-IN-8 (3 µM) or SP600125 (10
µM). Lysates were analysed for the expression of HPV 16/18 E6 and
E7. GAPDH was used as a loading control. Data shown are repre-
sentative of at least three independent experiments. E Representative
western blots of HeLa and CaSKi after transfection of a pool of siRNA
against c-Jun. Lysates were analysed for the expression of HPV 16/18
E6 and E7. GAPDH was used as a loading control. Data shown are
representative of at least three independent experiments. F ChIP-qPCR
analysis of c-Jun binding to the HPV18 URR in HeLa cells with or
without JNK-IN-8 (3 µM). Chromatin was prepared from HeLa cells
and c-Jun was immunoprecipitated using an anti-c-Jun antibody, fol-
lowed by RT-qPCR using primers specific to AP-1 binding sites in the
HPV18 URR enhancer or promoter region. c-Jun binding is presented
as percentage of input chromatin. G Luciferase reporter assay from
HeLa cells transfected with a HPV18 URR luciferase reporter and
treated with EGF (50 ng/mL, 8 h) with or without treatment with JNK-
IN-8 (3 µM). Promoter activity was measured using a dual-luciferase
system. Data are presented as relative to the GFP transfected control.
H qPCR analysis of HPV 16/18 E6 and E7 mRNA expression in HeLa
and CaSKi cells treated with EGF (50 ng/mL, 8 h) with or without
JNK-IN-8 (3 µM). U6 was used as a loading control. I Representative
western blots of HeLa and CaSKi treated with EGF (50 ng/mL, 8 h)
with or without JNK-IN-8 (3 µM). Lysates were analysed for the
expression of HPV 16/18 E6 and E7. GAPDH was used as a loading
control. Data shown are representative of at least three independent
experiments. J ChIP-qPCR analysis of c-Jun binding to the HPV18
URR in HeLa cells treated with EGF (50 ng/mL, 8 h), with or without
JNK-IN-8 (3 µM). Chromatin was prepared from HeLa cells and c-Jun
was immunoprecipitated using an anti-c-Jun antibody, followed by
RT-qPCR using primers specific to AP-1 binding sites in the HPV18
URR enhancer or promoter region. c-Jun binding is presented as
percentage of input chromatin. K qPCR analysis of HPV 16/18 E6 and
E7 mRNA expression in HeLa and CaSKi cells treated with EGF (50
ng/mL, 8 h) after transfection of a pool of siRNA against c-Jun. U6
was used as a loading control. L Representative western blots of HeLa
and CaSKi treated with EGF (50 ng/mL, 8 h) after transfection of a
pool of siRNA against c-Jun. Lysates were analysed for the expression
of HPV E6 and E7. GAPDH was used as a loading control. Data
shown are representative of at least three independent experiments.
Error bars represent the mean+/− standard deviation of a minimum of
three biological repeats. *P < 0.05, **P < 0.01, ***P < 0.001 (Stu-
dent’s t-test).
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which has previously been shown in skin tumours in which
the JUN gene has been deleted [32, 53, 78, 79]. Here,
disrupted JNK signalling reduced expression of EGF,
HBEGF and EGFR. Experiments using conditioned media
from control or JNK1/2 inhibitor-treated cells demonstrated
that the proliferative defect upon JNK1/2 inhibition was
rescued by the addition of soluble factors that were blocked
by a neutralising EGFR antibody, suggesting they function
through the EGFR. In confirmation of this, the addition of
EGF or HB-EGF to conditioned media from JNK1/2-
inhibited cells also rescued the proliferation defect. Neu-
tralising antibodies against EGF or HB-EGF not only
inhibited the restoration of proliferation, but inhibited pro-
liferation to a greater extend that the SP600125-treated
conditioned media. This suggests that these ligands may
also signal via receptors other than the EGFR. EGF has
been shown to activate ErbB4 homodimers, and both EGF
and HB-EGF can activate HER2/ErbB4 heterodimer
mediated mitogenic signalling [80]. Thus, the enhanced
proliferation defect observed upon addition of EGF and/or
HB-EGF neutralising antibodies may be due to the inhibi-
tion of mitogenic signalling through other ErbB receptors,
not just the EGFR. Together, our data indicate that impaired
EGFR/ErbB signalling contributes, in part, to the pro-
liferative defects observed in HPV+ cervical cancer cells
upon inhibition of JNK signalling.
HPV E6 has previously been shown to induce JNK/c-Jun
phosphorylation in lung cancer cells [81]; however, a clear
role for E6-mediated JNK/c-Jun signalling in cervical can-
cer cells is lacking. Our data demonstrate that the HPV E6
oncogene is responsible for JNK1/2 phosphorylation. We
further demonstrate that this is dependent on the PBM
found only in high-risk E6 proteins. As such, the induction
of JNK1/2 phosphorylation may be an oncogenic function
of E6. It is not clear how binding to cellular PDZ domains
modulates JNK1/2 phosphorylation. Several PDZ-domain-
Fig. 8 Schematic demonstrating E6-mediated JNK activation and
downstream signalling. HPV E6 induces JNK1/2 phosphorylation
and subsequent c-Jun/AP-1 activation. This drives the activation of
genes involved in cell proliferation, such as EGFR and EGF ligands,
which subsequently forms a positive feedback loop, driving JNK
activation and proliferation. JNK signalling also drives the expression
of genes involved in cell migration, invasion and EMT. Furthermore,
the JNK/c-Jun/AP-1 signalling axis is required for basal and EGF-
induced viral oncogene expression. Figure was created using BioR-
ender.com.
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containing targets of E6 are involved in cell polarity [82]; in
combination with oncogenic Ras mutants, loss of the cell
polarity proteins, and known E6 targets, Scribble and
DLG1, require JNK1/2 activation for tumourigenesis [83].
In addition, a Drosophila model of E6-mediated malig-
nancy demonstrated a key role for the polarity protein
MAGI [84]. Thus, HPV E6-mediated degradation of cell
polarity proteins may be required to induce JNK1/2
phosphorylation.
Constitutive expression of the viral oncogenes E6 and E7
is essential for cancer progression. However, our under-
standing of the regulation of viral oncogene expression by
host cell factors is incomplete. Previous data have demon-
strated that the viral URR contains transcription factor
binding sites necessary for viral oncogene expression
[60, 85]. Interestingly, two AP-1 binding sites have been
identified in the HPV18 URR, one in the enhancer region
and one in the promoter, which are important in viral
transcription [65]. Here, we demonstrate that the JNK sig-
nalling pathway is critical for the expression of HPV E6/E7.
Importantly, the JNK substrate c-Jun mediates the effect of
JNK activity on viral transcription, as recruitment of c-Jun
to the AP-1 binding sites in the URR is abolished upon
JNK1/2 inhibition. Furthermore, E6/E7 expression has
previously been demonstrated to be induced by EGFR
signalling [86, 87]; our data demonstrate that this requires
JNK activity.
Our study has uncovered the presence of a complex
positive feedback loop in HPV+ cervical cancer cells
(Fig. 8). In this pathway, HPV E6 activates JNK, which
then phosphorylates and activates c-Jun, which transacti-
vates host genes regulating cell growth and survival and can
also bind AP-1 sequences in the HPV URR to drive
expression of HPV E6/E7. Upregulated host factors include
both the EGFR and its ligands EGF and HB-EGF. Signal-
ling driven from the EGFR in turn activates JNK to
potentiate the pathway. The existence of this signalling loop




Cervical cytology samples were obtained from the Scottish
HPV Archive (http://www.shine/mvm.ed.ac.uk/archive.
shtml). The East of Scotland Research Ethics Service has
given generic approval to the Scottish HPV Archive as a
Research Tissue Bank (REC Ref 11/AL/0174) for HPV
related research on anonymised archive samples. Samples
are available for the through application to the Archive
Steering Committee (HPV Archive Application Ref 0034).
RNA and protein were extracted from the samples using
Trizol™ as described by the manufacturer (ThermoFisher
Scientific, USA).
TMA and immunohistochemistry
A cervical cancer TMA containing 39 cases of cervical
cancer and 9 cases of normal cervical tissue (in duplicate)
were purchased from GeneTex, Inc. (GTX21468). Slides
were deparaffinised in xylene, rehydrated in a graded series
of ethanol solutions and subjected to antigen retrieval in
citric acid. Slides were blocked in normal serum and incu-
bated in primary antibody (Phospho-SAPK/JNK (Thr183/
Tyr185) (81E11; 4668, Cell Signalling Technology (CST)))
overnight at 4 °C. Slides were then processed using the
VECTASTAIN® Universal Quick HRP Kit (PK-7800;
Vector Laboratories) as per the manufacturer’s instructions.
Immunostaining was visualised using 3,3’-diaminobenzi-
dine (Vector® DAB (SK-4100; Vector Laboratories)).
Phospho-JNK immunostaining quantification was auto-
mated using ImageJ with the IHC Profiler plug-in [88].
Histology scores (H-score) were calculated based on the
percentage of positively stained tumour cells and the
staining intensity grade [89]. The staining intensities were
classified into the following four categories: 0, no staining;
1, low positive staining; 2, positive staining; 3, strong
positive staining. H score was calculated by the following
formula: (3 × percentage of strong positive tissue) + (2 ×
percentage of positive tissue) + (percentage of low positive
tissue), giving a range of 0–300.
Cell culture
HeLa (HPV18+ cervical epithelial adenocarcinoma cells),
SW756 (HPV18+ cervical squamous carcinoma cells),
SiHa (HPV16+ cervical squamous carcinoma cells), CaSKi
(HPV16+ cervical squamous carcinoma cells), C33A
(HPV− cervical squamous carcinoma) and DoTc2-4510
(HPV−cervical squamous carcinoma) cells obtained from
the ATCC were grown in DMEM supplemented with 10%
Foetal Bovine Serum (FBS; ThermoFisher Scientific, USA)
and 50 U/mL penicillin (Lonza, USA). Primary NHKs
isolation from neonate foreskin tissues (ethical approval no.
06/Q1702/45) was performed in S. Roberts’ laboratory as
described previously [90] and were maintained in serum-
free medium (SFM; GIBCO, UK) supplemented with 25 µg/
mL bovine pituitary extract (GIBCO) and 0.2 ng/mL
recombinant EGF (GIBCO). All cells were cultured at 37 °
C and 5% CO2. The generation HPV18 containing NHKs
has been previously described [5].
All cells were negative for Mycoplasma during this
investigation. Cell identity was recently confirmed by STR
profiling.
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Plasmids, siRNA and reagents
Plasmids for HPV oncoproteins have been previously
described [29]. pAP1-luc, a luciferase reporter construct
regulated by a promoter sequence responsive to AP-1, has
been previously described [91]. p18URRL, a luciferase
reporter construct regulated by the HPV18 viral URR, has
been previously described [65] and was kindly provided by
Prof. Felix Hoppe-Seyler (German Cancer Research Center,
Heidelberg, Germany). pcDNA3 FLAG JNK1a1 (APF) and
JNK2a2 (APF) mutants were obtained from Addgene
(#13846 and #13761). c-Jun and ΔJunD were kindly pro-
vided by Prof. Simon Arthur (University of Dundee).
HPV16 E6 siRNA was purchased from Santa Cruz Bio-
technology (SCBT) and had the following sequence: 5′-
UGUGUACUGCAAGCAACAG-3′. The HPV18 E6 siR-
NAs were purchased from Dharmacon (GE Healthcare) and
had the following sequences: 5′-CUAACACUGGGUUA
UACAA-3′ and 5′-CTAACTAACACTGGGTTAT-3′. The
HPV16 and HPV18 E7 siRNA were as previously descri-
bed and were a kind gift from Prof. Eric Blair (University of
Leeds) [92, 93]. siRNA targetting c-Jun were purchased
from Qiagen (FlexiTube GeneSolution GS3725 for JUN;
SI03077599, SI00034678, SI00034671, SI00034664). The
small molecule inhibitors JNK-IN-8 (covalent, irreversible
JNK inhibitor), SP600125 (reversable JNK inhibitor),
U0126 (MEK1/2 inhibitor) and SB203580 (p38 inhibitor)
were purchased from Calbiochem. Human recombinant
EGF (236-EG) and HB-EGF (259-HE) were purchased
from R&D Systems. Human anti-EGF (MAB236-SP),
human anti-HB-EGF (AF-259-SP) and anti-mouse IgG1
control (MAB002) antibodies were purchased from R&D
Systems.
Transfections and mammalian cell lysis
Transfection of plasmid DNA was performed with a DNA
to Lipofectamine® 2000 (ThermoFisher) ratio of 1:2.5. 48 hr
post transfection, cells were lysed in lysis buffer for western
blot analysis, or reseeded into new plates for growth curve
analysis, colony formation assays or soft agar assays.
Transfection of siRNA was performed with a siRNA to
Lipofectamine® 2000 ratio of 1:2. 72-h post transfection
cells were lysed in lysis buffer for western blot analysis, or
reseeded into new plates for growth curve analysis, colony
formation assays or soft agar assays.
Luciferase reporter assays
Cells seeded into 12 well dishes were transfected with
reporter plasmids expressing firefly luciferase under the
control of an AP-1 responsive element using PEI or Lipo-
fectamine 2000. Where appropriate, cells were co-
transfected with a plasmid of interest, or treated as descri-
bed in the figure legend. To normalise for transfection
efficiency, a pRLTK Renilla luciferase reporter plasmid was
added to each transfection. After 24 h, samples were lysed
in passive lysis buffer (Promega, USA) and activity mea-
sured using a dual-luciferase reporter assay system (Pro-
mega) as described [91].
Western blot analysis
Equal amounts of protein from cell lysates were separated by
SDS PAGE and transferred onto a nitrocellulose membrane
by a semi-dry transfer method (Trans Blot® SD Semi-Dry
Transfer cell, Bio-Rad, USA). Membranes were blocked
with 5% milk solution before incubation with primary anti-
bodies at 1:1000 dilution unless otherwise stated: Phospho-
SAPK/JNK (Thr183/Tyr185) (81E11; 4668, CST), SAPK/
JNK (9252, CST), Phospho-ERK1/2 (Thr202/Tyr204)
(43705, CST), ERK1/2 (137F5; 4695, CST), Phospho-
MAPKAP2 (Thr334) (3007, CST), MAPKAP2 (12155,
CST), Phospho-c-Jun (Ser73) (D47G9; 3270, CST), c-Jun
(60A8; 9165, CST), JunD (D17G2; 5000, CST), EGFR
(E235; ab32077), Abcam) HPV 16/18 E6 (CBT; sc-460),
HPV 16 E7 (SCBT; sc-1587), HPV 18 E7 (8E2; ab100953,
Abcam), PARP-1 (9542, CST) FLAG (F1804, Sigma-
Aldrich), GFP (B-2; sc-9996, Santa Cruz Biotechnology
(SCBT)) and GAPDH (SCBT; sc365062) (1:5000) as a
loading control. Horseradish peroxidase (HRP)-conjugated
secondary antibodies (Sigma-Aldrich, USA) were used at a
1:5000 dilution. Proteins were detected using WesternBright
ECL (Advansta, USA) and visualised on X-ray film.
Chromatin immunoprecipitation
HeLa and CaSKi cells were treated with JNK-IN-8 or
transfected with a pool of c-Jun specific siRNA for the
required incubation time. Cells were processed for ChIP
analysis as previously described [94]. In brief, cells were
fixed in 1% formaldehyde for 10min at room temperature,
quenched in 0.25M glycine, and washed in ice-cold PBS.
Cells were harvested by scraping and then lysed in cell lysis
buffer (10 mM Tris-HCl, pH 8.0, 10mM NaCl, 0.2% NP-40,
10mM sodium butyrate, 50 μg/ml phenylmethylsulfonyl
fluoride (PMSF), 1× complete protease inhibitor). Nuclei
were collected by centrifugation at 2500 rpm at 4 °C and
resuspended in nuclear lysis buffer (50 mM Tris-HCl, pH 8.1,
10mM EDTA, 1% SDS, 10mM sodium butyrate, 50 μg/ml
PMSF, 1× complete protease inhibitor). Extracted chromatin
was then sonicated and chromatin concentration was deter-
mined. Approximately 100 µg of chromatin from each sample
was used for the experiment. c-Jun was immunoprecipitated
using a ChIP grade anti-c-Jun antibody (60A8; 9165, CST).
A/G magnetic beads were used to pull down the antibody-
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chromatin complex. To show antibody specificity, each of the
samples was pulled down with an IgG isotype control. The
immunoprecipitated chromatin was then processed for
quantitative PCR (qPCR); the primer sequences used are
available on request. Fold-enrichment compared to negative
control IgG isotype control was calculated as in [95].
RNA extraction, cDNA synthesis and quantitative
real Time-PCR
RNA extraction for qRT-PCR was performed using an E.Z.
N.A Total RNA Kit I (Omega bio-tek, USA). cDNA was
synthesised with 1 µg of input RNA and iScript cDNA
synthesis kit (Bio Rad, USA). qRT-PCR was performed on
the synthesised cDNA on a Corbett Rotor-Gene 6000 using
QuantiFast SYBR Green PCR kit (Qiagen, USA) and ana-
lysed using the ΔΔCT method [96] normalised to the U6
housekeeping gene. Primer sequences are available on
request.
Colony formation assay
Forty-eight or 72-h post-treatment or transfection, cells
were trypsinised and reseeded in a six-well plate at 500 cells
per well and left to incubate for 14–21 days. Colonies were
then stained (1% crystal violet, 25% methanol) and colonies
were counted manually. Each experiment was repeated a
minimum of three times.
Soft agar assay
Cells were treated or transfected as required. Sixty milli-
metre dishes were coated with a layer of 1% agarose
(ThermoFisher Scientific) in 2× DMEM (ThermoFisher
Scientific) supplemented with 20% FBS. Forty-eight hours
post-transfection, cells were trypsinised and added to 0.7%
agarose in 2× DMEM (ThermoFisher Scientific) supple-
mented with 20% FBS at 1000 cells/mL. Once set, DMEM
supplemented with 10% FBS and 50 U/mL penicillin was
added. The plates were then incubated for 14–21 days. Each
experiment was repeated at least three times. Visible colo-
nies were counted manually.
Flow cytometry
Cells were treated or transfected as required. 48 or 72-h
post-transfection, cells were harvested and fixed in 70%
ethanol overnight. The ethanol was removed, and cells
washed with PBS containing 0.5% (w/v) BSA. Cells were
stained with PBS containing 0.5% BSA, 50 μg/mL propi-
dium iodide (Sigma-Aldrich) and 5 μg/mL RNase (Sigma-
Aldrich) and incubated for 30 min at room temperature.
Samples were processed on a CytoFLEX S flow cytometer
(Beckman Coulter) and analysed using CytExpert (Beck-
man Coulter).
Annexin V assay
Annexin V apoptosis assay (TACS Annexin V kit; 4830-
250-K) was performed as indicated on the product data-
sheet. In brief, cells seeded in 6-well plates were treated or
transfected as required. Cells were trypsinised and collected
by centrifugation. 1 × 106 cells were then incubated in
100 μL Annexin V reagent (10 μL 10× binding buffer,
10 μL propidium iodide, 1 μL Annexin V-FITC (diluted 1 in
500) and 79 μL ddH2O) for 15 min at room temperature in
the dark. Samples were diluted in 1× binding buffer before
analysis by flow cytometry. Samples were processed on a
CytoFLEX S flow cytometer (Beckman Coulter) and ana-
lysed using CytExpert (Beckman Coulter).
TCPA data analysis
RPPA data from the Cancer Genome Atlas (TCGA) was
downloaded via The Cancer Proteome Atlas (TCPA) online
repository [37, 38]. Correlation between Phospho-SAPK/
JNK (Thr183/Tyr185), Phospho-ERK1/2 (Thr202/Tyr204)
and Phospho-p38 (Thr180/Tyr182) with the substrate
Phospho-c-Jun (Ser73) was assessed.
Statistical analysis
Data points from at least three individual, biological
repeats are shown in each graph. Unless otherwise indi-
cated in the figure legends, data were analysed using a
two-tailed, unpaired Student’s t-test and graphs were
prepared using the GraphPad Prism software (GraphPad,
USA). Error bars represent the mean+/− standard
deviation. Statistical significance was determined as fol-
lows: *P < 0.05, **P < 0.01, ***P < 0.001. Survival ana-
lysis was performed using the Kaplan–Meier method with
the log-rank test (univariate).
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